Curative Biotechnology Engages Sterling Pharmaceutical to Manufacture Metformin Ophthalmic Therapy

Manufacturing agreement advances company's metformin-based eye disease platform toward first-in-human clinical study.

Apr. 15, 2026 at 12:36pm

Got story updates? Submit your updates here. ›

A ghostly, translucent X-ray photograph revealing the intricate internal structure of an eye, with a glowing, neon-like optic nerve and retina, conceptually illustrating the potential of Curative Biotechnology's metformin-based therapy to address degenerative eye conditions.Curative Biotechnology's metformin-based ophthalmic therapy aims to address the complex inner workings of the eye, offering new hope for those suffering from degenerative eye diseases.Palm Beach Gardens Today

Curative Biotechnology, a biomedical company focused on rare disease therapies, has engaged Sterling Pharmaceutical Services to manufacture the clinical supply of its metformin-based topical ophthalmic formulation. This manufacturing engagement supports Curative's planned Phase 1 human clinical study in dry Age-Related Macular Degeneration (AMD) and its clinical K9 study targeting PDE6-associated retinal degeneration.

Why it matters

Establishing a manufacturing pathway is a critical milestone as Curative advances its metformin-based ophthalmology platform toward clinical evaluation. The company believes metformin may offer a novel therapeutic approach for treating degenerative eye diseases like AMD.

The details

Under the agreement, Sterling Pharmaceutical Services, a U.S.-based contract development and manufacturing organization (CDMO), will support production of Curative's topical metformin ophthalmic drops. The formulation is intended for use in Curative's planned first-in-human clinical study under a Cooperative Research and Development Agreement (CRADA) with the National Institutes of Health (NIH).

  • Curative recently completed a 1-for-150 reverse stock split as part of its strategy to improve capital structure and position the company for an OTCQB uplisting.
  • Curative is targeting a first-in-human clinical trial for its metformin-based topical ophthalmic formulation under the CRADA with the NIH.

The players

Curative Biotechnology, Inc.

A development-stage biomedical company focused on novel therapeutic approaches for rare diseases, with a primary focus on its degenerative eye disease platform supported by an exclusive license from the National Eye Institute (NEI) at the NIH.

Sterling Pharmaceutical Services, LLC

A U.S.-based contract development and manufacturing organization (CDMO) that specializes in formulation development and manufacturing of sterile pharmaceutical products.

National Institutes of Health (NIH)

The primary agency of the United States government responsible for biomedical and public health research, including Curative's Cooperative Research and Development Agreement (CRADA).

Got photos? Submit your photos here. ›

What they’re saying

“Engaging Sterling Pharmaceutical Services represents an important step in advancing our metformin-based ophthalmology platform toward clinical development.”

— Paul Michaels, Executive Chairman of Curative Biotechnology

“We are pleased to support Curative Biotechnology as it advances development of its topical ophthalmic program toward the clinic.”

— Robert T. Flynn, CEO of Sterling Pharmaceutical Services

What’s next

Curative is targeting a first-in-human clinical trial for its metformin-based topical ophthalmic formulation under the CRADA with the NIH.

The takeaway

Curative's engagement with Sterling Pharmaceutical Services to manufacture the clinical supply of its metformin-based eye disease therapy represents a critical milestone as the company advances its novel ophthalmology platform toward human trials, with the potential to offer new treatment options for degenerative eye conditions like Age-Related Macular Degeneration.